Neoplasms

All Conditions

Digestive System Diseases

Adenocarcinoma

Carcinoma, Hepatocellular

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

All Drugs and Chemicals

Hematinics

Vaccines

Liver Extracts

The using dosage,frequency and duration of cancer stem cell vaccine are still undetermined.

cancer stem cell vaccine

Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the immunologic interactions and effects of CSCs. In this study, the investigators examined the vaccination effects produced by CSC-enriched populations from histologically distinct murine tumors after their inoculation into different syngeneic immunocompetent hosts. Enriched CSCs were immunogenic and more effective as an antigen source than unselected tumor cells in inducing protective antitumor immunity.Immune sera from CSC-vaccinated hosts contained high levels of IgG which bound to CSCs, resulting in CSC lysis in the presence of complement.CTLs generated from peripheral blood mononuclear cells or splenocytes harvested from CSC-vaccinated hosts were capable of killing CSCs in vitro. Mechanistic investigations established that CSC-primed antibodies and T cells were capable of selective targeting CSCs and conferring anti-tumor immunity.

To assess the feasibility of generating CSC-loaded DC vaccines for clinical use, the investigators will harvest peripheral blood and tumor specimen from patients with hepatocellular cancer. The investigators will purify T, B cells and generate DCs from the PBMCs of the hepatocellular cancer patient.On the other hand, investigators will isolate ALDHhigh and ALDHlow tumor cells from the tumor specimen of the hepatocellular cancer patient using a similar protocol as investigators reported .

Aim 1: To demonstrate, in vitro, the relative cellular anti-hepatocellular cancer CSC immunity induced by hepatocellular cancer CSC-DC primed cytotoxic T cells.

Aim 2: To determine, in vitro, specific binding and lysis of hepatocellular cancer CSCs by antibodies produced by purified B cells from PBMCs stimulated with hepatocellular cancer CSC-DC.

Cancer Stem Cells Vaccine Therapy in Treating Hepatocellular Cancer Patients

Study of Cancer Stem Cell Vcccinie That as a Specific Antigen in Metastatic Adenocarcinoma of the Liver

University of Michigan

Fuda Cancer Hospital, Guangzhou

Gland and Hormone Related Diseases

Rare Diseases

Pancreatic Neoplasms

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Gastrointestinal Agents

Pancrelipase

Pancreatin

Most studies of cancer stem cells (CSC) involve the inoculation of cells from human tumors into immunosuppressed mice, preventing an assessment on the immunologic interactions and effects of CSCs. In this study, the investigators examined the vaccination effects produced by CSC-enriched populations from histologically distinct murine tumors after their inoculation into different syngeneic immunocompetent hosts. Enriched CSCs were immunogenic and more effective as an antigen source than unselected tumor cells in inducing protective antitumor immunity.Immune sera from CSC-vaccinated hosts contained high levels of IgG which bound to CSCs, resulting in CSC lysis in the presence of complement.CTLs generated from peripheral blood mononuclear cells or splenocytes harvested from CSC-vaccinated hosts were capable of killing CSCs in vitro. Mechanistic investigations established that CSC-primed antibodies and T cells were capable of selective targeting CSCs and conferring antitumor immunity.

To assess the feasibility of generating CSC-loaded DC vaccines for clinical use, the investigators will harvest peripheral blood and tumor specimen from patients with Pancreatic Cancer. The investigators will purify T, B cells and generate DCs from the PBMCs of the Pancreatic Cancer patient.On the other hand, investigators will isolate ALDHhigh and ALDHlow tumor cells from the tumor specimen of the Pancreatic Cancer patient using a similar protocol as investigators reported .

Aim 1: To demonstrate, in vitro, the relative cellular anti-Pancreatic Cancer CSC immunity induced by Pancreatic Cancer CSC-DC primed cytotoxic T cells.

Aim 2: To determine, in vitro, specific binding and lysis of Pancreatic Cancer CSCs by antibodies produced by purified B cells from PBMCs stimulated with Pancreatic Cancer CSC-DC.

Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer

Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Pancreas

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Nasopharyngeal Carcinoma

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Immunomodulating Agents

To assess the feasibility of generating CSC-loaded DC vaccines for clinical use, the investigators will harvest peripheral blood and tumor specimen from patients with Nasopharyngeal Cancer. The investigators will purify T, B cells and generate DCs from the PBMCs of the nasopharyngeal cancer patient.On the other hand, investigators will isolate ALDHhigh and ALDHlow tumor cells from the tumor specimen of the nasopharyngeal cancer patient using a similar protocol as investigators reported .

Aim 1: To demonstrate, in vitro, the relative cellular anti-nasopharyngeal cancer CSC immunity induced by nasopharyngeal cancer CSC-DC primed cytotoxic T cells.

Aim 2: To determine, in vitro, specific binding and lysis of nasopharyngeal cancer CSCs by antibodies produced by purified B cells from PBMCs stimulated with nasopharyngeal cancer CSC-DC.

The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine

Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic of the Nasopharynx

Colorectal Neoplasms

Intestinal Neoplasms

Colonic Diseases

Intestinal Diseases

Rectal Diseases

This is no cancer stem cells vaccine in this group

To assess the feasibility of generating CSC-loaded DC vaccines for clinical use, the investigators will harvest peripheral blood and tumor specimen from patients with colorectal cancer. The investigators will purify T, B cells and generate DCs from the PBMCs of the colorectal cancer patient.On the other hand, investigators will isolate ALDHhigh and ALDHlow tumor cells from the tumor specimen of the colorectal cancer patient using a similar protocol as investigators reported .

Aim 1: To demonstrate, in vitro, the relative cellular anti-colorectal cancer CSC immunity induced by colorectal cancer CSC-DC primed cytotoxic T cells.

Aim 2: To determine, in vitro, specific binding and lysis of colorectal cancer CSCs by antibodies produced by purified B cells from PBMCs stimulated with colorectal cancer CSC-DC.

A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer

Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Colorectal

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cancer Stem Cells Vaccine Therapy in Treating Hepatocellular Cancer Patients	NCT02089919	Neoplasms, Live...	cancer stem cel...	18 Years - 75 Years	Fuda Cancer Hospital, Guangzhou
Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer	NCT02074046	Neoplasms, Panc...	cancer stem cel...	18 Years - 75 Years	Fuda Cancer Hospital, Guangzhou
Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer	NCT02074046	Neoplasms, Panc...	cancer stem cel...	18 Years - 75 Years	Fuda Cancer Hospital, Guangzhou
The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine	NCT02115958	Neoplasms, Lung	cancer stem cel...	18 Years - 80 Years	Fuda Cancer Hospital, Guangzhou
The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine	NCT02115958	Neoplasms, Lung	cancer stem cel...	18 Years - 80 Years	Fuda Cancer Hospital, Guangzhou
Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer	NCT02074046	Neoplasms, Panc...	cancer stem cel...	18 Years - 75 Years	Fuda Cancer Hospital, Guangzhou
A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer	NCT02176746	Neoplasms,Color...	cancer stem cel...	18 Years - 80 Years	Fuda Cancer Hospital, Guangzhou
A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer	NCT02176746	Neoplasms,Color...	cancer stem cel...	18 Years - 80 Years	Fuda Cancer Hospital, Guangzhou

Spots Global Cancer Trial Database for cancer stem cell vaccine